Parkman Healthcare Partners LLC Takes $841,000 Position in Pulmonx Corporation $LUNG

Parkman Healthcare Partners LLC bought a new stake in Pulmonx Corporation (NASDAQ:LUNG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 646,564 shares of the company’s stock, valued at approximately $841,000. Parkman Healthcare Partners LLC owned 1.51% of Pulmonx at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Pulmonx during the 2nd quarter valued at about $149,000. Norges Bank acquired a new stake in shares of Pulmonx during the second quarter worth about $392,000. Jane Street Group LLC lifted its holdings in shares of Pulmonx by 3,328.7% during the second quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock worth $230,000 after purchasing an additional 86,046 shares during the period. Bank of America Corp DE lifted its holdings in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares during the period. Finally, Two Sigma Investments LP boosted its position in Pulmonx by 50.3% in the third quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after buying an additional 15,557 shares during the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LUNG. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, April 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Pulmonx Stock Performance

Shares of LUNG stock opened at $2.28 on Tuesday. Pulmonx Corporation has a 52-week low of $1.13 and a 52-week high of $2.89. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95. The stock has a market cap of $97.93 million, a PE ratio of -1.97 and a beta of 0.28. The business has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $1.51.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. The business had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. On average, equities analysts expect that Pulmonx Corporation will post -1.05 EPS for the current year.

Pulmonx Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.